Sphingolipids and phospholipids in insulin resistance and related metabolic disorders

Nat Rev Endocrinol. 2017 Feb;13(2):79-91. doi: 10.1038/nrendo.2016.169. Epub 2016 Oct 21.


Obesity, insulin resistance, type 2 diabetes mellitus and cardiovascular disease form a metabolic disease continuum that has seen a dramatic increase in prevalence in developed and developing countries over the past two decades. Dyslipidaemia resulting from hypercaloric diets is a major contributor to the pathogenesis of metabolic disease, and lipid-lowering therapies are the main therapeutic option for this group of disorders. However, the fact that dysfunctional lipid metabolism extends far beyond cholesterol and triglycerides is becoming increasingly clear. Lipidomic studies and mouse models are helping to explain the complex interactions between diet, lipid metabolism and metabolic disease. These studies are not only improving our understanding of this complex biology, but are also identifying potential therapeutic avenues to combat this growing epidemic. This Review examines what is currently known about phospholipid and sphingolipid metabolism in the setting of obesity and how metabolic pathways are being modulated for therapeutic effect.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Diabetes Mellitus, Type 2 / metabolism
  • Diabetes Mellitus, Type 2 / pathology
  • Dyslipidemias / metabolism
  • Dyslipidemias / pathology
  • Humans
  • Insulin Resistance / physiology*
  • Lipid Metabolism / physiology*
  • Metabolic Diseases / metabolism*
  • Metabolic Diseases / pathology
  • Phospholipids / metabolism*
  • Sphingolipids / metabolism*


  • Phospholipids
  • Sphingolipids